Diskussion zu MESOBLAST SP.ADRS 144A/5

👀 watchlist aufgenommen

Upcoming Milestones in Second Half FY2019: • Mesoblast intends to initiate BLA filing for marketing authorization of remestemcel-L following its FDA meeting scheduled for April 2019. • Mesoblast’s partner Tasly is planning to meet with the National Medical Products Administration of China to discuss the regulatory approval pathway for Revascor in China. • Mesoblast intends to meet with the FDA to discuss the pathway for approval of Revascor for the reduction in GI bleeding in patients with LVADs. • All patients in Mesoblast’s Phase 3 trial in MPC-06-ID for chronic lower back pain will complete their 12- month assessment for safety and efficacy.

🧐🧐🧐 Erster🤑🤑🤑